METTL16, by binding to the m6A site of the 3' end of prostate transmembrane protein androgen-induced protein 1 (PMEPA1), reduces its mRNA stability, thus inhibiting the proliferation of bladder cancer cells and increasing sensitivity to cisplatin, mediated by the autophagy pathway [217]. The gene discussed is METTL16; the disease is urinary bladder cancer.